ABT

Abbott Laboratories

99.67 USD

Last updated Oct 10, 08:16 UTC

Yesterday HIGH

$100.36

Yesterday LOW

$98.2

52w HIGH

$135.23

52w LOW

$81.97

EPS

1.31

PE

76.08

Next Earnings

Oct 21, 2026

Dividends yield

2.46%

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Abbott Laboratories stock is down -3.57% since 30 days ago. The dividend yield is 2.46% and its next earnings date is Oct 21, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56% of the previous 49 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

09 Oct 14:26	19 Mar, 2027	90.00	PUT	134	1614
09 Oct 14:40	19 Mar, 2027	90.00	PUT	85	1614
09 Oct 15:04	19 Mar, 2027	97.50	PUT	60	475
09 Oct 15:13	19 Mar, 2027	90.00	PUT	84	1614
09 Oct 16:42	19 Mar, 2027	90.00	PUT	161	1614
09 Oct 16:42	19 Mar, 2027	90.00	PUT	91	1614
09 Oct 19:06	19 Mar, 2027	90.00	PUT	114	1614
09 Oct 19:07	19 Mar, 2027	90.00	PUT	90	1614
09 Oct 19:07	19 Mar, 2027	90.00	PUT	79	1614
09 Oct 19:48	09 Oct, 2026	101.00	PUT	300	813

Advanced Data Unlock

Benzinga Insights

Tue Aug 25, 2026

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Vandana Singh

Fri Aug 21, 2026

Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation

Abbott agreed to pay $670 million to resolve the Gill lawsuit and 2,000 other NEC claims involving its specialty preterm infant formulas.
Benzinga Newsdesk

Thu Aug 20, 2026

Abbott Reaches ~$670M Settlement With Three Law Firms To Resolve Gill Case Involving ~2K Individuals Regarding Special Formulas For Pattern Infants

Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants.In
Benzinga Newsdesk

Thu Aug 20, 2026

Abbott’s Point-Of-Care Testing Products To Be Distributed In The UK Through Avricore Health's Healthtab Platform

HealthTab™ provides a complete, turnkey solution underpinning national pharmacy-based PoCT networks, including best-in-class instruments, consumables, onboarding, training, and ongoing support for participating sites.At
Benzinga Insights

Wed Aug 19, 2026

Recent Report Shows That Rep. Rick Allen Sold Up to $50K Worth of Abbott Laboratories Stock

An official report on August 18, 2026 reveals Representative Rick Allen's recent sale of Abbott Laboratories (NYSE:ABT) stock, valued between $15,001 and $50,000. The transaction took place on July 14, 2026, as per
Benzinga Insights

Mon Aug 17, 2026

Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock

Records from August 14, 2026 indicate that Representative Richard Dean Dr McCormick of Georgia made a sale of Abbott Laboratories (NYSE:ABT), valued between $25,025 and $375,000, with the transaction dated July 30, 2026
Chris Katje

Thu Aug 13, 2026

Congressman Ditches Blue Chip Stocks for Municipal Bonds: Here Are the Sales

A congressman reported selling stocks recently, while also investing in a municipal bond.
Benzinga Newsdesk

Thu Aug 13, 2026

Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to Outperform and announces $130 price target.
Benzinga Newsdesk

Tue Aug 11, 2026

Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Personalized Metabolic Insights More Actionable

The collaboration is designed to bring metabolic health insights into people's daily routines through a seamless, AI-powered experience. Through the Google Health app, Lingo users will be able to view glucose trends
Benzinga Newsdesk

Tue Jul 28, 2026

UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.

Rothschild & Co

Fri Oct 2, 11:52

buy

upgrade

Advanced Data Unlock

John G Stratton, Director

Wed Sep 30, 2026

ABT Recent Insider Trades and Stock Chart

397 shares awarded
Patricia Paola Gonzalez, Director

Wed Sep 30, 2026

ABT Recent Insider Trades and Stock Chart

333 shares awarded
Kevin T Conroy, Insider

Wed Sep 30, 2026

ABT Recent Insider Trades and Stock Chart

318 shares awarded
Nita Ahuja, Director

Wed Sep 30, 2026

ABT Recent Insider Trades and Stock Chart

318 shares awarded
Michael F Roman, Director

Wed Sep 30, 2026

ABT Recent Insider Trades and Stock Chart

381 shares awarded